FGF21 and neoplasm: In 2005, Kharitonenkov et al. first demonstrated that FGF-21 can act as a metabolic regulator to normalize metabolic disorders without inducing hypoglycemia and neoplasm (cited 1452 times) (Kharitonenkov et al., 2005), which resulted in a significant increase in FGF-21-related publications.